BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD4144 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD4144\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07215702-895@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:AZD4144: Phase 2 readout est. (NCT07215702)
DESCRIPTION:AZD4144\, phase 2.\nStudy: A Study to Investigate the Efficacy\
 , Safety\, and Tolerability of AZD4144in Participants With Sepsis-associat
 ed Acute Kidney Injury.\nEstimated primary completion: 11 February 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/azd4144#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07215702
URL:https://assetmemo.bio/drug/azd4144#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783308-895@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:AZD4144: Phase 1 readout est. (NCT07783308)
DESCRIPTION:AZD4144\, phase 1.\nStudy: A Phase I Study to Investigate the E
 ffect of Hepatic Impairment on the Pharmacokinetics\, Safety\, and Tolerab
 ility of AZD4144\nEstimated primary completion: 28 May 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/azd4144#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07783308
URL:https://assetmemo.bio/drug/azd4144#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
